Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes
CMV infection · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in CMV infection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
- Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes onlyRR 0.87 [0.63, 1.21]9 studies · 3099 participantsModerate